Novartis pulls rival to Roche’s risdiplam in SMA, says market limitedWhile Roche’s oral risdiplam has been tipped by some analysts to be a big contender in the market Share XNovartis pulls rival to Roche’s risdiplam in SMA, says market limitedhttps://pharmaphorum.com/news/novartis-pulls-rival-to-roches-risdiplam-in-sma-says-market-limited/
FDA cues up May verdict for Roche’s SMA challenger risdiplamThe FDA has started a priority review of Roche’s spinal muscular atrophy (SMA) candidate risdiplam, with a decision Share XFDA cues up May verdict for Roche’s SMA challenger risdiplamhttps://pharmaphorum.com/news/fda-cues-up-may-verdict-for-roches-sma-challenger-risdiplam/
Zolgensma hits the ground running, says NovartisNovartis’ Zolgensma gene therapy for spinal muscular atrophy is the most expensive drug in the world, but that Share XZolgensma hits the ground running, says Novartishttps://pharmaphorum.com/news/zolgensma-hits-the-ground-running-says-novartis/
AveXis rules out EU compassionate use of SMA gene therapy, says Biogen option is availableNovartis’ AveXis unit has given its reasons for refusing to supply its spinal muscular atrophy gene therapy Zolgensma Share XAveXis rules out EU compassionate use of SMA gene therapy, says Biogen option is availablehttps://pharmaphorum.com/news/avexis-rules-out-eu-compassionate-use-of-sma-gene-therapy-zolgensma/
Novartis in political row after denying Belgian toddler compassionate access to gene therapyThe controversy over Novartis’ ultra-pricey gene therapy Zolgensma has intensified after it allegedly refused to supply the one-off Share XNovartis in political row after denying Belgian toddler compassionate access to gene therapyhttps://pharmaphorum.com/news/novartis-in-political-row-after-denying-belgian-toddler-compassionate-access-to-gene-therapy/
Weekly roundup: More questions for Novartis in Zolgensma scandalIt’s been a tough month for Novartis, with the company facing a deepening scandal over data manipulation for Share XWeekly roundup: More questions for Novartis in Zolgensma scandalhttps://pharmaphorum.com/views-and-analysis/weekly-roundup-more-questions-for-novartis-in-zolgensma-scandal/
Novartis axed Avexis execs ahead of Zolgensma scandalThe plot thickens at Novartis, which is becoming embroiled in a scandal over falsification of data related to Share XNovartis axed Avexis execs ahead of Zolgensma scandalhttps://pharmaphorum.com/news/novartis-axed-avexis-execs-ahead-of-zolgensma-scandal/
US senators blast Novartis for Zolgensma data falsificationUS politicians have urged the FDA to come down hard on Novartis for failing to disclose manipulated data Share XUS senators blast Novartis for Zolgensma data falsificationhttps://pharmaphorum.com/news/us-senators-blast-novartis-for-zolgensma-data-falsification/
Second death in gene therapy trial prompts investigationA second death in a study of Novartis’ spinal muscular atrophy gene therapy Zolgensma (onasemnogene abeparvovec-xioi; AVXS-101) – Share XSecond death in gene therapy trial prompts investigationhttps://pharmaphorum.com/news/second-death-in-novartis-gene-therapy-trial-prompts-investigation/
